AbbVie Inc. (ABBV)
ABBV · Health Care · 
United States
AbbVie Inc. (ABBV) is a US company in the Health Care sector. The stock has its largest weight in XUHL (MSCI USA Health Care), at 7.66%. Anyone who holds an ETF containing AbbVie also has an indirect stake in the company.
Data and Charts: AbbVie
Key Data for AbbVie
AbbVie Stock Price Chart
The AbbVie chart shows daily closing prices and is set to the current year by default. The stock is up 29.1% year to date and up 29.2% over twelve months. The last recorded close on October 30, 2026, was $294.89, at 100% of the 52-week range.
Price series from our database since Jul 11, 2024, 580 daily values.
AbbVie Stock Performance
| Year to date | +29.1% | 1 year | +29.2% |
|---|---|---|---|
| 1 month | +12.7% | 3 months | +17.5% |
| Calendar year 2025 | +28.6% |
Measured in euros, AbbVie is up 35.7% year to date and up 33.6% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.
Alysly Data Analysis: AbbVie
What ETF Is AbbVie In?
AbbVie has above-average ETF coverage and is held by 22 of the 104 ETFs we track, which together follow 11 indices. That puts the stock in more ETFs than 85.1% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| XUHL / XUHC | MSCI USA Health Care | 7.66% | €76.59 |
| SPFS | MSCI World Health Care | 5.67% | €56.73 |
| XDWH | MSCI World Health Care | 5.67% | €56.67 |
| SPYD | S&P High Yield Dividend Aristocrats | 1.32% | €13.24 |
| SPYL / SPY5 | S&P 500 | 0.77% | €7.74 |
| XD9U / XD9D | MSCI USA | 0.77% | €7.72 |
| SXR8 | S&P 500 | 0.77% | €7.70 |
| XDEB | MSCI World Minimum Volatility | 0.65% | €6.49 |
| SWWD | MSCI World | 0.56% | €5.64 |
| SPPW | MSCI World | 0.56% | €5.64 |
| XDWD / XDWL | MSCI World | 0.56% | €5.64 |
| EUNL | MSCI World | 0.56% | €5.60 |
| WIMI | MSCI World IMI | 0.50% | €5.04 |
| SPYY | MSCI ACWI | 0.50% | €5.02 |
| IUSQ | MSCI ACWI | 0.50% | €5.00 |
| SPYI / SPSA | MSCI ACWI IMI | 0.46% | €4.65 |
| XDEW | S&P 500 Equal Weight | 0.23% | €2.25 |
The last column shows how much of €1,000 in one of these funds goes to AbbVie, based on each fund's latest holdings list.
US-listed ETFs holding AbbVie (weight per latest SEC filing): VYM 1.80%, IVV 0.69%, SPY 0.69%, VOO 0.69%, VTI 0.61%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
AbbVie Weight in iShares Core MSCI World (EUNL) Since 2019
In iShares Core MSCI World (EUNL), AbbVie had a weight of 0.27% on Sep 30, 2019 and 0.56% on Oct 29, 2026. The fund tracks the MSCI World. Its share peaked at 0.56% on Dec 30, 2022. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much AbbVie overlaps with the rest of a portfolio.
Which Tracked Investors Hold AbbVie?
AbbVie is not among the largest purchases in the quarter ending Jun 30, 2026. The list is led by GOOGL, DAL and NEBIUS GROUP N.V. The only manager we track that holds AbbVie reduced its position.
| Investor | Shares | Value | Quarter |
|---|---|---|---|
| Bridgewater Associates | 11,775 | $3M | reduced by 18,587 |
As of Jun 30, 2026. Based on quarterly filings with the US securities regulator, submitted up to 45 days after the reference date. The change counts shares, not price gains.
Stocks With ETF Exposure Similar to AbbVie
| Stock | Shared ETFs | r | 1 year | Annualized volatility | Net margin | Revenue growth |
|---|---|---|---|---|---|---|
| AbbVie | – | – | +29.2% | 26.5% | 6.9% | +8.6% |
 Abbott Laboratories | 22 | – | -14.8% | 24.0% | 14.7% | +5.7% |
 Cardinal Health | 22 | – | +31.9% | 26.3% | 0.7% | +14.2% |
 Cencora | 22 | – | -3.0% | 26.1% | 0.5% | +9.3% |
 McKesson Corporation | 21 | – | +20.5% | 28.4% | 1.2% | +12.4% |
| STERIS | 21 | – | -3.8% | 23.8% | 13.2% | +8.7% |
 Edwards Lifesciences Corporation | 21 | – | +10.2% | 25.0% | 17.7% | +11.5% |
 HCA Healthcare Inc | 21 | – | +1.4% | 29.0% | 9.0% | +7.1% |
 Eli Lilly and Company | 21 | +0.65 | +67.9% | 38.0% | 31.7% | +44.7% |
These stocks reach a portfolio through largely the same funds as AbbVie. “Shared ETFs” counts the funds that hold both.
Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical.
Fundamental Analysis: AbbVie
AbbVie Key Financials
Figures come from the SEC annual filing for the latest reported fiscal year (period end Dec 31, 2025).
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| FY ended Dec 2023 | 54.3 | 4.9 | 9.0% |
| FY ended Dec 2024 | 56.3 | 4.3 | 7.6% |
| FY ended Dec 2025 | 61.2 | 4.2 | 6.9% |
Latest Patents Granted to AbbVie
In the 52 weekly issues of the US patent office from Nov 4, 2025 to Oct 27, 2026, AbbVie received 6 utility patents and 2 design patents. That is 0.002% of all utility patents the US patent office granted in those weeks. The median time from filing to grant was 3.0 years.
| Granted | Patent | Title | Filed | Technology field |
|---|---|---|---|---|
| US 12715917 B2 | Methods of using anti-hemojuvelin (HJV) antibodies for treating myelofibrosis | C07K Chemistry; metallurgy | ||
| US 12715916 B2 | Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis | C07K Chemistry; metallurgy | ||
| US 12655210 B2 | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease | C07K Chemistry; metallurgy | ||
| US 12623820 B2 | Container cap and method of piercing a seal covering an opening of a container | B65D Containers and packaging | ||
| US 12570664 | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof | – | C07D Chemistry; metallurgy |
These are grants, not applications. The office usually publishes an application 18 months after the priority date; the grant tends to come much later. Owners counted: AbbVie Inc. and AbbVie Deutschland GmbH & Co. KG. Titles as published by the office; median time based on 4 patents with a known filing date.
The patent screener lists more grants, filterable by company, type and technology field. The M&A and patents page compares companies.
Technical Analysis: AbbVie
AbbVie Risk Metrics
The close on Oct 30, 2026, was the highest since our series began on Jul 11, 2024. When the S&P 500 rose or fell 1%, AbbVie moved 0.17% on average in the opposite direction (past 252 trading days). The correlation of -0.08, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of AbbVie.
What AbbVie Correlates With
| Instrument | r | −1 … +1 |
|---|---|---|
| Eli Lilly and Company | +0.65 | |
| Johnson & Johnson | +0.65 | |
| Royalty Pharma Plc Class A | +0.65 | |
| Biogen Inc. | +0.61 | |
| Astrazeneca plc | +0.60 | |
| Vertex Pharmaceuticals Incorporated | +0.60 | |
| Bloom Energy Corporation Class A | -0.52 | |
| Eaton Corp. Plc | -0.51 | |
| Lumentum Holdings Inc. | -0.51 |
The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.
